11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Daratumumab

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Daratumumab

Daratumumab

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treat Rev. 2015;41(10):827-35.

  2. Posch D, Rabitsch W, Wohlfarth P, Leiner M, Porpaczy E, Drach J et al. Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience. Oncology. 2017;93(5):295-301.

  3. Yusuf AA, Natwick T, Werther W, Felici D, Mahue M, Bridges KR et al. A retrospective analysis to examine factors associated with mortality in Medicare beneficiaries newly diagnosed with multiple myeloma. Curr Med Res Opin. 2016;32(12):1989-1996.

  4. Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I et al. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer. 2009;45(6):1017-27.

  5. DARZALEX (daratumumab) DailyMed,. DailyMed [www]. US National Library of Medicine. [updated 2019-10-05, cited 2019-02-03].

  6. Darzalex (daratumumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2019-01-14, cited 2019-02-03].

  7. Yan X, Clemens PL, Puchalski T, Lonial S, Lokhorst H, Voorhees PM et al. Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. Clin Pharmacokinet. 2018;57(4):529-538.

  8. Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018;378(6):518-528.

  9. Cejalvo MJ, Ribas P, de la Rubia J. The safety of daratumumab for the treatment of multiple myeloma. Expert Opin Drug Saf. 2017;16(6):753-760.

  10. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]

  1. Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treat Rev. 2015;41(10):827-35.
  2. Posch D, Rabitsch W, Wohlfarth P, Leiner M, Porpaczy E, Drach J et al. Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience. Oncology. 2017;93(5):295-301.
  3. Yusuf AA, Natwick T, Werther W, Felici D, Mahue M, Bridges KR et al. A retrospective analysis to examine factors associated with mortality in Medicare beneficiaries newly diagnosed with multiple myeloma. Curr Med Res Opin. 2016;32(12):1989-1996.
  4. Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I et al. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer. 2009;45(6):1017-27.
  5. DARZALEX (daratumumab) DailyMed,. DailyMed [www]. US National Library of Medicine. [updated 2019-10-05, cited 2019-02-03].
  6. Darzalex (daratumumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2019-01-14, cited 2019-02-03].
  7. Yan X, Clemens PL, Puchalski T, Lonial S, Lokhorst H, Voorhees PM et al. Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. Clin Pharmacokinet. 2018;57(4):529-538.
  8. Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018;378(6):518-528.
  9. Cejalvo MJ, Ribas P, de la Rubia J. The safety of daratumumab for the treatment of multiple myeloma. Expert Opin Drug Saf. 2017;16(6):753-760.
  10. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]